PD-L1 Expression in Non-Clear Cell Renal Cell Cancer

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.

Clinical Pearls:

  • In the past, it was thought that immune therapies worked better in clear-cell kidney cancer compared to non-clear cell kidney cancer
  • A study found that non-clear cell tumors expressed PD-L1 on their tumor surface, begging the question if these patients might respond to PD-1 or PD-L1 antibodies
  • Patients with non-clear cell tumors should be included in future trials that include PD-1 or PD-L1 antibodies